You are here

Article Text

Article menu
Download PDFPDF
Commentary
Surveillance programmes for colorectal cancer in inflammatory bowel disease: have we got it right?

https://doi.org/10.1136/gut.2008.152009

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Funding: CNB is supported, in part, by a Research Scientist Award of the Crohn’s and Colitis Foundation of Canada.

    • Competing interests: CNB is on the advisory boards of Axcan Pharma, Abbott Canada, Shire Canada and UCB Canada, and has consulted to Bristol Myers Squibb.

    Linked Articles